RegenETP, Inc. (RGTPQ)
- Previous Close
0.0699 - Open
0.0310 - Bid --
- Ask --
- Day's Range
0.0310 - 0.0699 - 52 Week Range
0.0100 - 0.4400 - Volume
970 - Avg. Volume
2,191 - Market Cap (intraday)
515,599 - Beta (5Y Monthly) 2.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6000 - Earnings Date May 17, 2024 - May 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 12, 2016
- 1y Target Est
--
RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. The company was formerly known as PolarityTE, Inc. and changed its name to RegenETP, Inc. in August 2023. RegenETP, Inc. is headquartered in Salt Lake City, Utah.
www.polarityte.comRecent News: RGTPQ
Performance Overview: RGTPQ
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGTPQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGTPQ
Valuation Measures
Market Cap
515.60k
Enterprise Value
-2.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.24
Price/Book (mrq)
0.04
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-56.67%
Return on Equity (ttm)
-54.97%
Revenue (ttm)
73k
Net Income Avi to Common (ttm)
-8.3M
Diluted EPS (ttm)
-0.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
6.39M
Total Debt/Equity (mrq)
23.77%
Levered Free Cash Flow (ttm)
-11.39M
Research Analysis: RGTPQ
Company Insights: RGTPQ
RGTPQ does not have Company Insights